

www.ispor.org



Thank you for joining.
The presentation will start at 4:00PM ET.
There is no audio being transmitted at this time.
Audio is provided via your computer speakers, please check your settings.

2020 General Business Meeting

Presented at Virtual ISPOR 2020

June 10, 2020

www.ispor.org



2020 General Business Meeting

Presented at Virtual ISPOR 2020

June 10, 2020



Nancy Devlin, PhD

President
ISPOR

President's Remarks

Antitrust Compliance Statement

- ISPOR has a policy of strict compliance with both United States, and other applicable international antitrust laws and regulations.
- Antitrust laws prohibit competitors from engaging in actions that could result in an unreasonable restraint of trade.
- ISPOR members must avoid discussing certain topics when they are together, including, prices, fees, rates, profit margins, or other terms or conditions of sale.
- Members have an obligation to terminate any discussion, seek legal counsel's advice, or, if necessary, terminate any meeting if the discussion might be construed to raise antitrust risks.
- The Antitrust policy is available on the ISPOR website.

Today's Discussion

- **Call to Order and President's Report**—Nancy Devlin, PhD, 2019-2020 President
- **CEO's Report, including Financial and Audit Committee Report** — Nancy S. Berg, CEO and Executive Director
- **ISPOR Publications Reports**
 - *Value in Health* Editors-in-Chief Report—C. Daniel Mullins, PhD
 - *Value in Health Regional Issues* Co-Editor-in-Chief Report—Manuel Espinoza, MD, MSc, PhD
 - *Value & Outcomes Spotlight* Editor-in-Chief Report—David Thompson, PhD
- **Member Open Discussion**—ISPOR Members
- **Adjournment**—Nancy Devlin

Motion from ISPOR Members

As per Article XI, Section 1 of the Society's Bylaws:

Any member of the Society who is in good standing may submit a motion for consideration by the members as a whole or by the Board of Directors. All such motions must be submitted in writing to the CEO & Executive Director at least 48 hours prior to the General Meeting, unless notice is waived by the President. Motions presented at the General Business Meeting will be submitted to the Board of Directors for consideration.

Motion submitted by Dr Junling Wang asking the Board to consider establishing a subgroup for academic members, those interested in working in academia, postdocs, and early stage faculty members.



President (2019-2020)
Nancy J. Devlin, PhD



President-Elect (2019-2020)
Jens Grueger, PhD



Past President (2019-2020)
Federico Augustovski, MD, MSc,
PhD



Director (2017-2020)
Meindert Boysen, PharmD



Director (2018-2021)
Jalpa A. Doshi, PhD



Director (2017-2020)
Stephanie R. Earnshaw, PhD



Director (2017-2020)
Jan Elias Hansen, PhD



Director (2018-2021)
Neil Hawkins, MSc, MBA, PhD



Director (2018-2021)
Rok Hren, PhD, MSc



Director (2018-2021)
Raoh-Fang (Jasmine) Pwu, PhD



Treasurer (2017-2020)
Zeba M. Khan, RPh, PhD



CEO & Executive Director
Nancy S. Berg

Welcome New 2020-2021 Board Members



President-Elect (2020-2021)
Isao Kamae, MD, DrPH



Director (2020-2023)
Eberechukwu Onukwugha, MS, PhD



Director (2020-2023)
Kalipso Chalkidou, MD, PhD



Director (2020-2023)
David Thompson, PhD




Treasurer (2020-2023)
Sean D. Sullivan, PhD

Scientific Priorities Initiative



Strategic Plan Update 2024




Diversity and Inclusion



ISPOR Conferences—Plenary Speaker Diversity

2016-2019 ISPOR Conferences—Female Plenary Speakers/Panelists




Virtual ISPOR 2020—Panel Gender Diversity

Invited Sessions (Plenaries)



■ Gender Diverse
 ■ All Female
 ■ All Male

Submitted Sessions (IPs, WSs)




■ Gender Diverse
 ■ All Female
 ■ All Male

Virtual ISPOR 2020 vs ISPOR 2019


Submitted Sessions Diversity (Issue Panels, Workshops)

ISPOR 2019



■ Gender Diverse
 ■ All Female
 ■ All Male

Virtual ISPOR 2020




■ Gender Diverse
 ■ All Female
 ■ All Male

ISPOR Scientific Priorities—A New Initiative

- To guide & inform ISPOR's mission-critical activities
- To meet the evolving needs of healthcare decision makers
- Placing ISPOR to be proactive in shaping the future of HEOR
- What are the big ideas, new methods and new applications, where breakthrough HEOR can advance our science and our impact?
- Ambitious timeline: 2020
- Input sought from ISPOR membership groups
- Working group coordinated by ISPOR Chief Scientist





Our members are ISPOR;
ISPOR is the heart of HEOR;
& HEOR is the foundation
for improving healthcare decisions.



Thank you!



Nancy S. Berg

CEO and Executive Director
ISPOR

Update and Financial Report

CEO's Report

ISPOR Annual Report



Strategic Plan Update Emphasizes



-  ----- Scientific Priorities
-  ----- Engaging Members Globally
-  ----- Increasing Collaboration
-  ----- Making an Impact

ISPOR Offices Lawrenceville (Princeton), NJ USA

- ISPOR is a not-for-profit education organization
- \$16.7-million in net assets with \$13.3 million liquid. Net assets, or reserves, are maintained to support investments or to help sustain membership activities during downtimes.
- Serving 10,000-plus members and 10,000-plus Chapter members living in 114 countries and more than 125 ISPOR groups
- ISPOR-owned office encompasses 18,000 square feet of space and houses the majority of staff
- Expenses well controlled




Financial Audit

- Larson Allen LP was hired as ISPOR's Auditor in 2015.
- Audit reviews internal procedures and seeks to identify deficiencies in internal controls relating to financial reporting which are deemed material weaknesses.
- Audit Results
 - ISPOR is doing well financially
 - No material weaknesses noted during audit
 - No internal control letter to be issued
 - No audit adjustments


2019 Audit Financial Statements: Summary

	12/31/19 Audited Financial Statements
REVENUE	\$17,604,789
EXPENSES	\$15,038,046
CHANGE IN NET ASSETS (Addition)	\$ 2,566,743
NET ASSETS 12.31.19	\$17,949,965



Income & Expenses




Net Assets



December 31, 2019 Assets & Liabilities



ISPOR, HEOR ...and COVID-19







Publications Reports

Editors-in-Chief Remarks

www.ispor.org



Value in Health

Presented by:

C. Daniel Mullins, PhD
Editor-in-Chief

Highlights

Themed Sections

2019

Evolution of EuroQol

Back to the Future (20th Anniversary Issue)

Curative Therapies

2020

HTA Around the World

Value-Based Contracting

Precision Medicine

Health Preferences Research

Annual Submissions

2018 = 1046

2019 = 1167

2020 = 445 (data as of 5/13/20; on track to exceed 1200 papers)

Key Statistics

Impact Factor: **5.037**

Rejection Rate: **82%** (nearly 72% are rejected without external peer review)

www.ispor.org



Value in Health Regional Issues

Presented by:

Manuel Espinoza, MD, MSc, PhD
Editor-in-Chief

Highlights

New Editorial Structure

Implemented in January 2020

Overarching Editor-in-Chief

Deputy Editors (1 for each region)

Associate Editors (5 for each region)

Annual Submissions

	<u>2018</u>	<u>2019</u>	<u>2020</u> (as of 5/13/20)
Totals:	183	200	95
Asia	67	84	46
CEEWAA	51	46	26
Latin America	65	70	23

2019 Rejection Rate: 57.1%

Themed Section

COVID-19: Case Studies from the Region [\[Editors to invite at least 1 study from each region\]](#)

www.ispor.org



Value & Outcomes Spotlight

Presented by:
David Thompson, PhD
Editor-in-Chief

Highlights

COVID-19 Coverage in March/April 2020 Issue

- Letter From the Editor: ISPOR in the Time of Corona
- From the President: COVID-19—A Call to Action for Health Economics and Outcomes Researchers
- Special Feature: The COVID-19 Virus in Wuhan, China: A Personal Story
- Q&A: Christian Lindmeier (WHO Spokesperson) and Mirjam Kretzschmar, PhD (Infectious Disease Modeler, University Medical Centre Utrecht)

2020 Feature Articles

- New Digital Healthcare Ecosystem (January/February)
- The State of Health Technology Assessment (March/April)
- Innovative Pricing Models (May/June)
- Behavioral Economics (July/August)
- Current State of Real-World Evidence (September/October)
- Deep Dive Into Stakeholder Perspectives (November/December)

New Editor-in-Chief

- Appointment of new Editor to begin on July 1, 2020
- I would like to personally thank ISPOR and all readers of *Value & Outcomes Spotlight* for their support during my tenure



ຂໍຂອບໃຈທ່ານ ສູບສາສຸນາສູກ ດັນຍາວາດ ви благодариме

nirringrazzak

di ou mesi

dank je

tack

aitäh

ありがとう

σας ευχαριστώ

dziękuję

buíochas a ghabháil leat

তোমাকে ধন্যবাদ

ತಾಶಕ್ಕೂರ ಕೊಶೊನೊಂ

gratias agimus tibi

danke

gracias

thank you

graziemerci

ngyabonga

Дзякуй go raibh maith agat

sukriya

terima kasih

salamat

тәшәккүр

köszönöm

謝謝

kiitos

thank you

благодаря

děkuji

감사합니다

takk

diolch i chi

falemnderit

gracies

dank u paldies

спасибо

grazas

dankie

eskerrik asko

cam on ban

pakka pér

mochchakkeram

teşekkür ederim

hvala

kop khun krap

multumesc

obrigado

אָדאַקע

אָדאַקע

אָדאַקע

אָדאַקע

אָדאַקע

אָדאַקע


אָדאַקע

אָדאַקע

אָדאַקע

אָדאַקע

Member Discussion



www.ispor.org



Adjournment



ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.

ISPOR's community of more than 20,000 individual and chapter members from 120+ countries includes a wide variety of healthcare stakeholders, including researchers, academicians, regulators and assessors, public and private payers, healthcare providers, industry, and patient representatives. The Society's leadership has served as an unbiased resource and catalyst for innovation in the field for more than 20 years.

www.ispor.org



ISPOR

Improving healthcare decisions